Clinical Cancer Research Meeting Calendar AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bohana-Kashtan, O.
Right arrow Articles by Civin, C. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bohana-Kashtan, O.
Right arrow Articles by Civin, C. I.
Clinical Cancer Research Vol. 11, 968-970, February 2005
© 2005 American Association for Cancer Research

The Biology Behind

Profiling Tumor Counterattack: Do Fas Ligand–Containing Microvesicles Reduce Anticancer Immunity?

Osnat Bohana-Kashtan1 and Curt I. Civin1,2

1 Division of Immunology and Hematopoiesis, Sidney Kimmel Comprehensive Cancer Center, Departments of Oncology and 2 Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: Curt I. Civin, Department of Pediatrics, Johns Hopkins Oncology Center, 1650 Orleans Street, Baltimore, MD. Phone: 410-955-8816; Fax: 410-955-8897; E-mail: civincu{at}jhmi.edu.

Cancer cells co-opt several physiologic regulatory mechanisms to resist immune attack. It has been suggested that one such cancer-corrupted immunologic checkpoint may be tumor cell expression of Fas ligand (FasL) to "counterattack" Fas-sensitive infiltrating T (and natural killer) effector cells. The Fas pathway functions physiologically to limit the size of antigen-stimulated immune cell clones via a process termed activation-induced cell death. In addition, physiological cellular expression of FasL may protect immune privileged organs, such as eye, brain, testis, and placenta, from immune damage by inducing apoptosis of invading Fas-sensitive inflammatory cells (1).

Several types of human cancers express FasL and mediate apoptosis of Fas-sensitive T cells in vitro (2–4). Tumor cell FasL expression has been associated with decreased numbers of tumor-infiltrating lymphocytes and increased numbers of apoptotic lymphocytes in human colon and esophageal carcinomas (5, 6). Cancer cell FasL expression has also been correlated with (a) the ability of tumor cells to inactivate neutrophils, (b) tumor growth rate, and (c) patients' prognosis (7–12). Moreover, FasL expression levels were found to be higher in liver metastases of human colorectal carcinoma than in matched primary tumors (13). Based on such findings, it has been suggested that FasL-expressing tumor cells locally counterattack tumor-infiltrating lymphocytes, thereby establishing immune privilege for the cancer mass.

This FasL counterattack hypothesis has been challenged by studies showing that artificially enforced overexpression of FasL in tumors enhanced tumor rejection rather than tumor survival (14, 15) . Adding to the controversy are key technical issues, such as the specificity of the anti-FasL antibodies used, and the need to distinguish FasL counterattack by tumor cells from apoptosis due to physiological activation-induced cell death (16–19). In addition, whereas metalloprotease-mediated release of FasL from tumors has been proposed as a mechanism of counterattack, it has been found that the resulting soluble form of FasL functions more as a competitive inhibitor of cell membrane FasL than as a (weak) agonist. Finally, tumor cell expression of other proteins, such as transforming growth factor-ß (20, 21), may be equal or more important factors in tumor immune resistance. Perhaps a reasonable synthesis is to predict that further investigations will demonstrate that expression of FasL is only one of a complex set of mechanisms by which certain cancers may inhibit immune attack.

In this issue of Clinical Cancer Research, Kim et al. investigated a nuanced version of this FasL counterattack mechanism to explain the apoptosis of circulating T lymphocytes and the associated decreased T cell receptor-associated signaling molecule {zeta}-chain expression that they had previously documented in patients with oral squamous cell carcinoma (22). This research group also observed apoptosis of circulating T lymphocytes and decreased expression of T cell receptor-{zeta}-chain in patients with squamous cell carcinoma of the head and neck and malignant melanoma (23–25), and they suggested that these tumors have immunosuppressive effects on circulating lymphocytes, as well as on tumor-infiltrating lymphocytes. Andreola et al. (26) showed that melanoma cells generated FasL-containing membrane microvesicles (FasL-MVs) that mediated apoptosis of T lymphoid cells, and Taylor et al. (27) found similarly immunosuppressive FasL-MVs in the sera of patients with ovarian cancer. Kim et al. now report that FasL-MVs isolated from sera of patients with oral squamous cell carcinoma, but not from normal controls, induced apoptosis of FasL-sensitive T lymphoid target cells and down-regulated expression of the T cell receptor-{zeta}-chain. Both apoptosis and {zeta}-chain down-regulation were partially inhibited by either an anti-Fas neutralizing monoclonal antibody or a peptide caspase inhibitor. Levels of FasL-MVs in the serum of patients with oral squamous cell carcinoma correlated positively with levels of apoptosis induction and negatively with {zeta}-chain expression. These results, along with the similar observations in ovarian cancer (27), suggest that FasL-MVs (possibly along with the other proapoptotic molecules) from tumor cells can impair not only lymphocytes in the local tumor microenvironment (i.e., tumor-infiltrating lymphocytes), but also distant lymphocytes (Fig. 1). It is important to note that these FasL-MVs were shown to contain the membranous full-length form of FasL, rather than the less potent (and even inhibitory, see above) metalloprotease-cleaved soluble FasL molecule. Furthermore, this report includes preliminary results in a small series of patients indicating that the level of FasL-MVs might serve as a prognostic factor in oral squamous cell carcinoma.



View larger version (38K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1 FasL-MV-mediated tumor counterattack. Tumor cells attack tumor-specific circulating T cells by releasing microvesicles containing FasL-MVs into the blood. Note that because the tumor cells also express FasL on their cell membranes, they can also directly attack T cells that infiltrate the tumor site.

 
What are the next steps? As noted by Kim et al., the source of the shed FasL-MVs has not yet been proven to be the cancers. Further studies are needed to test the possibility that FasL-MVs are merely the product of activation-induced cell death of normal activated lymphocytes. It will also need to be determined if FasL-MVs are found in sick control patients without cancer, especially patients with immune disorders. Of course, large prospective studies are needed to test the prognostic utility of serum levels of FasL-MVs. However, FasL-MVs may prove more important as part of the complex profile of the conflagration between the cancer and the immune system than simply as a clinical prognostic factor.


   FOOTNOTES
 
Commentary on Kim et al., p.1010

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 1/ 3/05; accepted 1/ 3/05.


   REFERENCES
Top
 REFERENCES
 

  1. Ferguson TA, Green DR, Griffith TS. Cell death and immune privilege. Int Rev Immunol 2002;21:153–72.[CrossRef][Medline]
  2. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075–82.[Abstract/Free Full Text]
  3. Villunger A, Egle A, Marschitz I, et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997;90:12–20.[Abstract/Free Full Text]
  4. Gastman BR, Atarshi Y, Reichert TE, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59:5356–64.[Abstract/Free Full Text]
  5. Bennett MW, O'Connell J, O'Sullivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160:5669–75.[Abstract/Free Full Text]
  6. Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-ß expression. Br J Cancer 2003;89:1345–51.[CrossRef][Medline]
  7. Chen YL, Chen SH, Wang JY, Yang BC. Fas ligand on tumor cells mediates inactivation of neutrophils. J Immunol 2003;171:1183–91.[Abstract/Free Full Text]
  8. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion? Nat Med 1996;2:1361–6.[CrossRef][Medline]
  9. Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 2003;201:268–77.[CrossRef][Medline]
  10. Reimer T, Herrnring C, Koczan D, et al. FasL:Fas ratio—a prognostic factor in breast carcinomas. Cancer Res 2000;60:822–8.[Abstract/Free Full Text]
  11. Ito Y, Monden M, Takeda T, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2000;82:1211–7.[CrossRef][Medline]
  12. Botti C, Buglioni S, Benevolo M, et al. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 2004;10:1360–5.[Abstract/Free Full Text]
  13. Mann B, Gratchev A, Bohm C, et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999;79:1262–9.[CrossRef][Medline]
  14. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 1997;94:13862–7.[Abstract/Free Full Text]
  15. Seino K, Kayagaki N, Fukao K, Okumura K, Yagita H. Rejection of Fas ligand-expressing grafts. Transplant Proc 1997;29:1092–3.[CrossRef][Medline]
  16. Restifo NP. Countering the ‘counterattack’ hypothesis. Nat Med 2001;7:259.[CrossRef][Medline]
  17. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002;80:131–7.[CrossRef][Medline]
  18. Restifo NP. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000;6:493–5.[CrossRef][Medline]
  19. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001;7:271–4.[CrossRef][Medline]
  20. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998;282:1714–7.[Abstract/Free Full Text]
  21. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor ß in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004;100:2281–91.[CrossRef][Medline]
  22. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137–45.[Abstract/Free Full Text]
  23. Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999;5:1263–73.[Abstract/Free Full Text]
  24. Kuss I, Saito T, Johnson JT,Whiteside TL. Clinical significance of decreased {zeta} chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999;5:329–34.[Abstract/Free Full Text]
  25. Dworacki G, Meidenbauer N, Kuss I, et al. Decreased {zeta} chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001;7:947s–957s.
  26. Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303–16.[Abstract/Free Full Text]
  27. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3-{zeta} by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003;9:5113–9.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
O. Goldberger, I. Volovitz, A. Machlenkin, E. Vadai, E. Tzehoval, and L. Eisenbach
Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape
Cancer Res., May 1, 2008; 68(9): 3450 - 3457.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bohana-Kashtan, O.
Right arrow Articles by Civin, C. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bohana-Kashtan, O.
Right arrow Articles by Civin, C. I.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online